Amgen Inc. $AMGN Shares Sold by Callan Family Office LLC

Callan Family Office LLC cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 31,795 shares of the medical research company’s stock after selling 1,557 shares during the quarter. Callan Family Office LLC’s holdings in Amgen were worth $11,514,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Keebeck Wealth Management lifted its position in shares of Amgen by 4.0% in the second quarter. Keebeck Wealth Management now owns 2,529 shares of the medical research company’s stock valued at $916,000 after acquiring an additional 98 shares in the last quarter. Blue Capital Inc. acquired a new stake in Amgen during the second quarter worth about $240,000. Keating Financial Advisory Services Inc. raised its position in shares of Amgen by 7.0% during the 2nd quarter. Keating Financial Advisory Services Inc. now owns 1,289 shares of the medical research company’s stock valued at $467,000 after buying an additional 84 shares during the period. OneAscent Family Office LLC raised its position in Amgen by 37.6% in the second quarter. OneAscent Family Office LLC now owns 874 shares of the medical research company’s stock valued at $317,000 after purchasing an additional 239 shares during the period. Finally, Impax Asset Management Group plc lifted its position in Amgen by 4.6% in the second quarter. Impax Asset Management Group plc now owns 18,289 shares of the medical research company’s stock valued at $6,623,000 after buying an additional 796 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $439.33 on Friday. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44. Amgen Inc. has a 52 week low of $269.77 and a 52 week high of $443.20. The company has a market cap of $237.51 billion, a P/E ratio of 27.30, a PEG ratio of 3.13 and a beta of 0.41. The company has a 50-day moving average price of $379.03 and a 200 day moving average price of $361.95.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a return on equity of 124.14% and a net margin of 22.95%.Amgen’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $6.02 earnings per share. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Research analysts predict that Amgen Inc. will post 22.92 earnings per share for the current year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be issued a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a dividend yield of 2.3%. Amgen’s dividend payout ratio is currently 62.65%.

Analyst Ratings Changes

A number of research analysts have commented on the company. Robert W. Baird upped their price target on Amgen from $215.00 to $230.00 and gave the stock an “underperform” rating in a research note on Wednesday, August 5th. The Goldman Sachs Group set a $389.00 price target on shares of Amgen in a report on Friday, June 5th. UBS Group increased their price objective on Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a report on Wednesday, August 5th. Canaccord Genuity Group increased their target price on shares of Amgen from $366.00 to $384.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Bank of America increased their price objective on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, fourteen have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $380.43.

Insider Buying and Selling at Amgen

In other news, SVP Rachna Khosla sold 1,252 shares of the firm’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $416.43, for a total transaction of $521,370.36. Following the completion of the transaction, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This trade represents a 16.35% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the firm’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president directly owned 7,340 shares of the company’s stock, valued at $2,951,854.40. The trade was a 28.81% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock worth $2,540,926 in the last three months. 0.85% of the stock is owned by corporate insiders.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.